CAR T-Cell Therapy for Multiple Myeloma Pipeline Experiences Rapid Expansion as Over 5+ Leading Companies Advance Novel Therapies
Discover the latest drugs and treatment options in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Dive into DelveInsight's comprehensive report today! @ CAR T-Cell Therapy for Multiple Myeloma Pipeline Outlook
Key Takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report
In July 2025, Janssen Research & Development LLC announced a study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
DelveInsight's CAR T-Cell Therapy for Multiple Myeloma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for CAR T-Cell Therapy for Multiple Myeloma treatment.
The leading CAR T-Cell Therapy for Multiple Myeloma Companies such as Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others.
Promising CART-Cell Therapy for Multiple Myeloma Pipeline Therapies such as Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others.
Stay ahead with the most recent pipeline outlook for CAR T-Cell Therapy for Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ CAR T-Cell Therapy for Multiple Myeloma Treatment Drugs
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Profile
Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the multiple myeloma treatment.
JNJ-68284528: Janssen Biotech
Janssen's drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status.
The CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma Treatment.
CAR T-Cell Therapy for Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
CAR T-Cell Therapy for Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market
Explore groundbreaking therapies and clinical trials in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New CAR T-Cell Therapy for Multiple Myeloma Drugs
CAR T-Cell Therapy for Multiple Myeloma Companies
Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others.
CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type
CAR T-Cell Therapy for Multiple Myeloma Products have been categorized under various Molecule types such as
Small molecules
Natural metabolites
Monoclonal antibodies
Product Type
Unveil the future of CAR T-Cell Therapy for Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ CAR T-Cell Therapy for Multiple Myeloma Market Drivers and Barriers
Scope of the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report
Coverage- Global
CAR T-Cell Therapy for Multiple Myeloma Companies- Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others.
CART-Cell Therapy for Multiple Myeloma Pipeline Therapies- Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others.
CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on CAR T-Cell Therapy for Multiple Myeloma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ CAR T-Cell Therapy for Multiple Myeloma Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
CAR T-Cell Therapy for Multiple Myeloma: Overview
Pipeline Therapeutics
Therapeutic Assessment
CAR T-Cell Therapy for Multiple Myeloma – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals
Early Stage Products (Phase I)
PHE 885: Novartis
Drug profiles in the detailed report…..
Pre-clinical Stage
JNJ-68284528: Janssen Biotech
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
CAR T-Cell Therapy for Multiple Myeloma Key Companies
CAR T-Cell Therapy for Multiple Myeloma Key Products
CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs
CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers
CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Multiple Myeloma Analyst Views
CAR T-Cell Therapy for Multiple Myeloma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
1 Reason to Buy Solana (SOL)
Key Points Solana hasn't kept up with the rest of the crypto market. However, the lightning-fast blockchain is seeing significant growth in tokenized RWAs. 10 stocks we like better than Solana › Solana (CRYPTO: SOL) has recently disappointed investors. It's down 1% over the last year (as of July 30), which looks particularly poor considering that crypto has been in a bull market. In fact, out of the top 10 cryptocurrencies by market cap, Solana has performed the worst over the last year. But circumstances can change quickly in the crypto market, and Solana has a new use case that could help it rebound. Solana is a hotspot for tokenization This year, Solana has seen rapid growth in tokenized real-world assets (RWAs). These are crypto tokens on a blockchain that represent a physical asset or a financial instrument. For example, you can buy tokenized equities on Solana that are equivalent to stock shares. The selection of equities is a lot smaller than what you'd find in your brokerage account, at least for the time being. But you can invest in tokenized versions of dozens of companies, including Tesla, Palantir Technologies, and Nvidia. The number of RWA holders on Solana has increased by 1,281% this year to nearly 63,000. Total RWA value has increased by 176% to $479 million, and Solana could be on the cusp of greater growth in this area. BioSig Technologies recently announced it will invest as much as $1.1 billion in physical gold bullion for its treasury. It also plans to issue gold-backed crypto tokens using Solana. This could potentially triple Solana's RWA value and attract more users to its blockchain. The early stages of tokenized RWAs RWAs have just started taking off, but they have the potential to drastically increase the value locked onto blockchain ecosystems. Solana's speed and ultra-cheap transactions make it well suited for RWA applications. Despite Solana's lackluster performance over the last year, it's still an exciting cryptocurrency investment that may be poised for a big move. Should you invest $1,000 in Solana right now? Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
an hour ago
- Globe and Mail
How Should Investors View Stablecoins: As a Utility or a Speculative Asset?
Key Points Stablecoins exist to move fiat currency value onto blockchains. They shouldn't ever grow much in value. Not all of these assets are equally safe or equally easy to use. 10 stocks we like better than Tether › Cash has always been the grease of capitalism, shuffling quietly from buyer to seller so the real business can get done. In crypto, something still has to play that crucial but unglamorous role, and that something is the stablecoin. Without a trustworthy on-chain dollar to use as a medium of exchange, every trade would involve swapping in and out of volatile tokens that often experience 10% moves in a day. Yet the headlines that push stablecoins into the spotlight tend to trumpet new regulations, billion-dollar market caps, fresh exchange listings, and -- occasionally -- dramatic deviation from their intended fixed value (de-pegging) that leaves destruction in its wake. That can make them look like the next hot trade rather than the digital equivalent of the crumpled bills in a supermarket till. To decide whether they belong in your portfolio at all, it pays to separate their utilitarian purpose from their real but frequently misunderstood risks. When you hear about stablecoins, you're hearing about cash At the simplest level, a stablecoin is a crypto token designed to track the price of a target fiat currency, -- usually the U.S. dollar -- so that people can send, store, and settle value on-chain without worrying about minute-by-minute price swings. USDC (CRYPTO: USDC) is the poster child for this model, and the second largest of all stablecoins. Every token is said to be backed 1-for-1 by cash and short-term U.S. Treasury bills held by the issuer Circle, with independent attestations posted monthly. Meanwhile, Circle's own valuation ballooned to roughly $60 billion as USDC's circulating supply hit $61.3 billion in June -- though the company now has a market cap of $46.2 billion, whereas its coin's value now is about $64 billion. Tether's stablecoin, USDT (CRYPTO: USDT) -- the sector's biggest stablecoin with a market cap of $164 billion -- publishes daily snapshots that claim its reserves exceed liabilities, though critics note that the level of detail in its disclosures varies. And, in late 2024, Ripple USD (CRYPTO: RLUSD) entered the fray, pitched by Ripple Labs as an institutional investor-friendly alternative that lives on XRP 's chain but is quickly finding retail takers, too. Viewed through that lens, holding a stablecoin is less an investment than a convenience fee. You trade the rock-bottom risk of a bank deposit for the same amount of purchasing power embedded on 24/7 blockchain rails and near-instant transaction settlements. If your goal is long-term capital appreciation, then assets like other cryptocurrencies or equities or even fairly conservative bonds will almost certainly do incalculably more heavy lifting. But if you routinely move funds between exchanges, stake in yield pools, or settle invoices with global partners, the ability to snap digital dollars across chains is invaluable. These risks could turn utility into liability Stablecoins are, at this point of their maturity as an asset, riskier than holding the equivalent amount of cash. For stablecoins, stability hinges on three pressure points that every investor should keep in mind. First, there's asset issuer quality. Fully collateralized coins can break their peg if the issuer's reserves prove shakier than advertised or if they are frozen by regulators. If you're going to hold significant value in a stablecoin, read the attestation reports and audits, not the marketing copy. And check the price history for any evidence of past de-pegging. Second, there are chain and bridge risks to consider. In the same vein, there are also interoperability risks or, more colloquially, the risk that the stablecoin you own is not compatible with the blockchain that you want to do business on. As an example, a USDT stored on Ethereum is not the same asset as a USDT bridged to Solana, and moving between chains relies on third-party bridges that have been prime hacker targets, and which also tend to incur fees. Developers are racing to build native cross-chain standards, but for now, every hop between chains introduces another potential point of failure. To be clear, this issue is common to many types of cryptocurrencies, but it's important to identify it specifically in the context of stablecoins because of the (incorrect) assumptions that investors often have about them due to their interchangeability with cash. Third, not all pegs rely on holding old-fashioned cash -- much to the detriment of their holders. Algorithmic models in the past have attempted to hold parity through burn -and- mint mechanics, which reduce or add coins to the supply to maintain the $1 equilibrium point. But during times of market turmoil, rapid withdrawals can lead to oversupply and breaking the peg. Investors who mistake such structures for a boring digital dollar end up learning the hard way that complexity and leverage can masquerade as stability right up until they don't. So where does that leave the long-term investor? Treat stablecoins as working capital, not high-yield savings. It's not a bad idea to diversify across at least two issuers, and favor tokens that publish frequent, detailed reserve attestations. If you operate on multiple chains, consider maintaining the native version of a coin on each chain rather than relying on bridges. Lastly, remember that new jurisdictions, from the U.S. Congress to Hong Kong's monetary authority, are rolling out licensing regimes that may well reshuffle the leaderboard of the top or best stablecoins in short order. Should you invest $1,000 in Tether right now? Before you buy stock in Tether, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tether wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
an hour ago
- Globe and Mail
What Happened to BlackBerry (BB) Stock This Year?
Key Points BlackBerry stock has gone nowhere over the past year. The company is relying on its QNX and SecuSmart divisions to drive its near-term growth. The stock is not as cheap as it appears to be given its growth potential. 10 stocks we like better than BlackBerry › BlackBerry (NYSE: BB) was once synonymous with smartphones, but it lost that booming market to the Apple iPhone and Android-powered devices. It eventually stopped producing phones entirely and reinvented itself as an Internet of Things (IoT) and cybersecurity software provider, but it's still struggling to expand in those saturated markets. The stock has traded flat in 2025 as the S&P 500 is up 8% year to date. Let's see why BlackBerry is trailing the broad market this year and where it might be headed over the next 12 months. BlackBerry's two core growth engines Most of BlackBerry's recent growth has been driven by two acquisitions. First, it acquired QNX, the world's most popular embedded operating system (OS) for vehicles, back in 2010. That acquisition helped it profit from the secular growth of the connected and driverless vehicle markets. In 2023, it launched BlackBerry IVY, a cloud-based connected-vehicle platform which was built on QNX and co-developed with Amazon Web Services. BlackBerry rebranded its entire IoT business as QNX earlier this year, and it expects more automotive design wins to drive its results long-term. In fiscal 2025 (which ended this past February), the QNX segment's revenue rose 10% year over year and accounted for 44% of BlackBerry's top line. Second, BlackBerry acquired the cybersecurity company Cylance in 2019 for $1.4 billion. That acquisition was aimed at strengthening its cybersecurity software business, but it faced stiff competition from bigger and faster-growing competitors like Palo Alto Networks and CrowdStrike. In February, it sold Cylance's endpoint security assets to Arctic Wolf for $160 million in cash and equity. In fiscal 2025, BlackBerry's revenue from its secured communications segment (which houses its cybersecurity services, SecuSmart secure messaging and call services, and other security tools) dipped 4% year over year but still accounted for 51% of its top line. BlackBerry previously leveraged its patents to generate high-margin royalties and licensing fees, but it sold most of that portfolio over the past three years to raise fresh cash. As a result, its licensing revenue plunged 90% in fiscal 2025 and only accounted for 5% of its top line. What will happen to BlackBerry over the next year? BlackBerry expects to generate $508 million to $538 million in revenue in fiscal 2026, which would represent a 2% decline at the midpoint. This includes a 10% to 14% hit to secured communications revenue stemming from the Cylance sale, though the company continues to gain more SecuSmart customers. For QNX, management is guiding for 10% full-year growth at the midpoint of its $250 million to $270 million range. On the bottom line, adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) should range between a 14% decline and 3% growth. For fiscal 2027, however, analysts expect revenue and adjusted EBITDA to rise 9% and 18%, respectively, as QNX and SecuSmart gain new customers. Is it the right time to buy BlackBerry stock? With an enterprise value of $2.2 billion, BlackBerry isn't much of a bargain at four times this year's sales. It also trades at 27 times forward adjusted EBITDA. Insiders have been net sellers of the stock over the past 12 months too. If BlackBerry manages to meet analysts' expectations and still trades at 27 times its forward adjusted EBITDA by the beginning of fiscal 2027, its shares could rise 16% over the next 12 months. If either of its two main segments stumble, however, its valuation multiples would likely contract, driving the stock lower. That's why I don't think BlackBerry stock is worth buying yet. Should you invest $1,000 in BlackBerry right now? Before you buy stock in BlackBerry, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BlackBerry wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
